Testosterone optimization in women

The premise

Female testosterone optimization is the most underprescribed, most stigmatized intervention in postmenopausal medicine. The mainstream framing treats androgen replacement in women as adjunctive — something you reach for after estrogen and progesterone are dialed in, and only if a patient is willing to accept the label "off-label." The Nimbus position is the opposite. In a symptomatic postmenopausal woman with low Free T, testosterone is a primary intervention — sitting in the same first-line tier as estradiol and progesterone, with its own optimal target, its own preferred route, and its own contraindication set.

This module trains the prescriber and the pharmacist to (a) confirm symptoms plus a Free T below optimal, (b) initiate the compounded labial cream as the default route, (c) interpret the numeric Free T target across vendors, (d) preserve the patient's DHT signal rather than block it, and (e) document the off-label use carefully. The female protocol diverges sharply from male TRT — in route, in dose, in target, and in what we expect (or do not expect) the molecule to do at the receptor.

Pre-test

Why testosterone is primary, not adjunctive, in female HRT

Female testosterone has been treated as an afterthought for two reasons that do not survive scrutiny. First, there is no FDA-approved female testosterone product in the US — every preparation a postmenopausal woman might use is compounded, every dose is off-label, and the prescribing culture has internalized the absence of an approved product as evidence the intervention is unvalidated. Second, the fear that women on testosterone will be "masculinized" has shaped guidelines more than the underlying physiology has.

Both arguments collapse under the data. The 2019 global consensus statement on testosterone therapy in women^{[Davis-2019-consensus]} endorsed testosterone for postmenopausal HSDD and acknowledged the absence of an FDA-approved product as a regulatory gap, not a clinical one. The downstream clinical reality — fatigue, low libido, blunted sexual response, low muscle mass, mood — maps to androgen deficiency in postmenopausal women with the same internal consistency that low E2 maps to vasomotor symptoms.

The Nimbus framing: if you would not withhold estradiol from a symptomatic postmenopausal woman because there is no perfect female-dosing trial, you do not withhold testosterone for the same reason.^{[nimbus-policy-03-testosterone-women]}

The labial cream protocol — 20 mg/mL, 1/4 mL QHS — and why this route

The Nimbus default initiation is a compounded testosterone cream at 20 mg/mL, applied 1/4 mL (5 mg) to the labia / vaginal vestibule QHS. This is the preferred route — not the upper inner arm, not sublingual, not injection, not pellets — for three reasons that are mechanistic, not stylistic.

1. Systemic exposure. Vestibular skin absorbs testosterone systemically with pharmacokinetics comparable to other thin-skinned application sites.
2. Local DHT. 5-alpha-reductase converts a fraction of locally applied testosterone to DHT in the labial and clitoral tissue. DHT is the dominant androgen at the clitoral androgen receptor and is required for the clitoral engorgement and orgasmic response that motivate the therapy in the first place.
3. GSM overlap. Topical testosterone applied vaginally improves vaginal pH, vaginal health score, and lactobacilli population on a 12-week timescale in the Fernandes 2016 RCT^{[Fernandes-2016-vaginalT]} — comparable to topical estradiol on those endpoints, without endometrial change.

The labial route therefore covers libido, orgasmic response, GSM, and systemic levels in a single application. No other route delivers all four.

Alternates — 40 mg/mL cream, micro-dose click, pellets

A subset of patients cannot or will not use the labial route. The alternates, in approximate order of how often Nimbus reaches for them:

• Step-up cream — 20 mg/mL 1/2 mL QHS or 40 mg/mL 1/4 mL QHS (each delivering ~10 mg/day) when 5 mg/day has not produced symptom or Free T response at 8–12 weeks.
• Upper inner-arm topical, 1/4 mL daily — systemic only; loses the local DHT benefit. Reasonable when labial application is declined.
• Sublingual tablet 2–6 mg QD–BID for patients who prefer an oral-route micro-dose.
• Oral compounded USP testosterone 30–50 mg QAM — acceptable when topical and sublingual routes fail. Never methyltestosterone; the alkylated congener is hepatotoxic and is not used at Nimbus in either sex.
• Subcutaneous injection 6–10 mg twice weekly — off-label; reserved for patients in whom topical absorption is inadequate.
• Pellets ~2 mg/kg (range 50–200 mg) every 3–6 months — off-label and used with caution. Supraphysiologic peaks are common when pellet dose pushes Free T above the 6–8 pg/mL Quest band; the Nimbus position is that pellets in women are an exception, not a default. TODO(citation): Nimbus pellet-titration policy (internal).

Numeric targets — Quest 6–8 pg/mL vs. LabCorp 3–4 pg/mL Free T

The cross-vendor mismatch is the single most common point of confusion when reading a female testosterone result. Quest and LabCorp use different Free T assay methodologies; the optimal band on each vendor is approximately:

• Quest: Free T 6–8 pg/mL.
• LabCorp: Free T 3–4 pg/mL.
• Total T (either vendor): 200–300 ng/dL — supportive, but secondary to Free T when the two disagree.^{[nimbus-policy-03-testosterone-women]}

The LabConverter widget below applies the empirical Quest↔LabCorp factor. Authors and reviewers should treat the converter output as a sanity check — a value at the edge of the optimal band on one vendor will sit at the corresponding edge on the other.

A note on SHBG: women on oral E2, oral contraceptives, or the vaginal ring frequently run elevated SHBG, which depresses bioavailable T and surfaces or worsens deficiency. SHBG is useful to interpret a discrepancy between Total T (which may look adequate) and Free T (which is the symptom-correlated metric).

DHT preservation — why 5-alpha-reductase inhibitors are blocked in this protocol

In men, DHT is the dominant androgen at the prostate androgen receptor and the driver of the benign prostatic hyperplasia / androgenic alopecia complex that 5-alpha-reductase inhibitors (finasteride, dutasteride) are designed to suppress. In women, DHT is the dominant androgen at the clitoral androgen receptor. The clinical effects we want from female testosterone — clitoral engorgement, orgasmic response, GSM benefit — are downstream of DHT, not of testosterone itself.

The Nimbus standing protocol therefore excludes 5-alpha-reductase inhibitors in women on testosterone optimization. Co-prescribing finasteride or dutasteride strips the local DHT signal the labial route was specifically chosen to generate. If a patient on female testosterone develops scalp thinning, the workup is:

1. Confirm ferritin ≥80 ng/mL (low iron is a frequent and reversible driver).
2. Confirm thyroid is optimized (FT3 in the optimal band).
3. Trial topical minoxidil 5% (or oral minoxidil 1.25 mg/day) as the first-line dermatologic intervention.
4. Only after those steps fail, and with explicit informed consent regarding post-finasteride syndrome, consider dutasteride 0.5 mg twice weekly as last-line — and counsel the patient that this option is reserved for those committed to remaining on testosterone long-term.

Spironolactone (up to 100 mg BID) is acceptable for confirmed androgenic acne or hirsutism in women; it is not a substitute for dose reduction or for the ferritin/thyroid workup.

Female testosterone does not aromatize meaningfully — implications for E2 expectations

In men, a fraction of administered testosterone aromatizes to estradiol, and the rising E2 is sometimes the dose-limiting issue. In women, exogenous testosterone at physiologic-range doses does not meaningfully aromatize to E2.^{[nimbus-policy-03-testosterone-women]} This has two practical consequences.

1. Do not gate female testosterone titration on E2 trends. A rising or falling E2 in a woman on labial cream is being driven by her estradiol therapy (or its absence), not by her testosterone.
2. Do not deploy aromatase inhibitors as part of female testosterone management. The mechanism that justifies aromatase inhibition in a small number of male TRT cases does not apply.

Symptom monitoring — libido, energy, mood, body composition

The Nimbus reassessment at 8–12 weeks is symptom-driven first and lab-driven second. The domains we expect to move:

• Libido and HSDD. Spontaneous desire and responsive arousal both improve; this is typically the earliest and most patient-noticed change.
• Orgasmic response. Clitoral sensitivity and orgasmic intensity improve on the labial route specifically — this is the DHT-mediated signal and is a reason to prefer the labial route over systemic-only alternates.
• Energy and mood. Reduction in fatigue and anxiety; mood-stabilizing effect reported across cohort literature.
• Body composition. Lean mass and strength improve on a slower timescale (months, not weeks); this is the rationale for not declaring the protocol a failure at the 8-week mark on body-composition grounds alone.

Lab confirmation: Total T plus Free T, drawn 4–5 hours after the morning medications, with the labial cream applied the previous evening.

Safety blocks — pregnancy/lactation, breast cancer, etc.

The female testosterone protocol is gated by the following blocks, applied at intake and re-confirmed at every reassessment:

• Active or history of hormone-sensitive cancer (breast, endometrial, ovarian). Oncology clearance required.
• Pregnancy or trying to conceive. Testosterone is teratogenic to the female fetus; this is an absolute block.
• Breastfeeding. Absolute block for the lactation window.
• Severe hepatic impairment. Caution with oral USP testosterone; topical routes are preferred when oral cannot be avoided.
• Severe baseline acne, hirsutism, or androgenic alopecia. Relative blocks — counsel, optimize ferritin and thyroid first, and start at the lower end of the dose range.

A patient on a combined OCP, ring, or Depo provera frequently needs testosterone because the contraceptive raises SHBG and lowers bioavailable T; the contraceptive is not a contraindication to female testosterone, but it does change the SHBG interpretation.

Mid-module checkpoint

Role-specific guidance

Cheat sheet

Post-test

Module evaluation